Drug combination for advanced triple negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a combination of three drugs—lenvatinib (a targeted therapy that blocks blood vessel growth), sintilimab (an immunotherapy that helps your immune system attack cancer), and nab-paclitaxel (a chemotherapy)—as the first treatment for triple negative breast cancer that has spread. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your breast cancer is triple negative and has spread or come back.
- You have not yet had any treatment for the cancer that has spread.
- If you had chemotherapy before, it was at least 6 months before the cancer came back.
- You are generally well enough to carry out daily activities (ECOG 0 or 1).
- Your heart, liver, and kidney function are within acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs—cromolyn, TQB2102, and panpulimab—for women with triple negative breast cancer that has not responded to previous immunotherapy. The goal is to see if this combination can shrink or slow the cancer and give you another treatment option.
This trial tests a combination of two drugs, tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy), as the first treatment for advanced triple-negative breast cancer that has spread to the bones. It aims to see if this combination can help shrink or control the cancer.
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
This study tests a new way to choose treatment for advanced triple-negative breast cancer, based on a special analysis of your tumor. The goal is to find a treatment that works better for your specific cancer type.
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.